Moleculin Biotech Inc: 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study
Moleculin Biotech公司:在研究中,89%的大腸癌患者都是具有“預後不良”的細胞遺傳學和/或基因突變的病例。
Moleculin Biotech Inc: 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study
Moleculin Biotech公司:在研究中,89%的大腸癌患者都是具有“預後不良”的細胞遺傳學和/或基因突變的病例。
譯文內容由第三人軟體翻譯。